Karius Strategic Collaboration

Expanding access to infectious disease testing

Mayo Clinic Laboratories has entered a strategic collaboration with Karius to expand access to advanced metagenomic infectious disease diagnostics. Through this collaboration, clinicians can order the Karius Spectrum™ and Karius Focus™ | BAL tests, which use next‑generation sequencing to rapidly identify a broad range of pathogens. These tests support timely, informed clinical decision‑making for patients with complex infections, particularly those who are immunocompromised.

Broad pathogen identification

Karius Spectrum™ and Karius Focus™ | BAL use metagenomic next‑generation sequencing to detect a comprehensive range of pathogens from plasma and bronchoalveolar lavage fluid, delivering actionable diagnostic insights.

Rapid, actionable results

With a 24‑hour laboratory processing time, these tests provide timely results that support faster diagnosis, targeted antimicrobial therapy, and reduced reliance on invasive procedures.

Focused on complex patient needs

This strategic collaboration expands access to precision diagnostics designed to address the challenges of diagnosing serious and hospital‑acquired infections, especially in immunocompromised patients.

“Expanding our metagenomic sequencing portfolio strengthens our ability to accurately identify causative pathogens and support targeted clinical decision‑making for patients with complex infections.”

William Morice II, M.D., Ph.D., President and CEO, Mayo Clinic Laboratories

Resources

Learn more Metagenomics sequencing

Learn more Bronchoalveolar lavage fluid metagenomic testing

Learn more Plasma metagenomic testing

Learn more Metagenomics: Diagnosing the undiagnosable